Allurion appoints Eli Lilly veteran Keith Johns to Board of Directors

ALLURION TECHNOLOGIES, INC.

Keith Johns appointed as Class III director effective Sept 2, 2024; board expands from 7 to 8 members.
Johns spent 25 years at Eli Lilly, most recently leading Global Marketing and Alliance Management for Diabetes and Obesity.
His expertise includes GLP-1 drug launches and obesity market strategy.
Compensation will follow standard non-employee director policy as described in prior SEC filings.
Johns also serves as COO of Adipo Therapeutics, focusing on brown adipose tissue obesity treatments.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Keith Johns

Class III director

ALUR · ALLURION TECHNOLOGIES, INC.

Effective: 2024-09-02
Filed: September 4, 2024, 7:59 PM ET

On September 2, 2024, the Board of Directors (the "Board") of Allurion Technologies, Inc. ("Allurion" or the "Company") appointed Keith Johns to the Board as a Class III director to fill a vacancy created by an increase in the size of the Board from seven members to eight members, effective September 2, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Keith Johns was appointed as Class III director at ALLURION TECHNOLOGIES, INC..

Action: appointed
Role: Class III director

Exact text from the filing

On September 2, 2024, the Board of Directors (the "Board") of Allurion Technologies, Inc. ("Allurion" or the "Company") appointed Keith Johns to the Board as a Class III director to fill a vacancy created by an increase in the size of the Board from seven members to eight members, effective September 2, 2024.

View on SEC.gov

ALLURION TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-103546

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.